Concurrent exposure to lead, selenium or monensin effects on hepatic porphyrin levels in broiler chickens during acute toxicosis

Acute Toxicosis of selenium and monensin produced a significant increase in uro- and corpoporphyrin levels. Results also indicated that acute lead toxicosis increased liver porphyrins levels of broiler chickens. This was further aggravated when selenium or monensin were administrated concurrently. This experiment indicated presence of an interaction between lead and selenium or monensin in elevation of porphyrins in the liver tissue of the broiler chickens

Effect of mixed administration of selenium and fenitrothion on pathomorphological pattern in internal organs in rats

Mixed intoxication in rats with sodium selenite (0.40 ppm) and fenitrothion (40 mg/kg bm.) resulted in pathomorphological changes in stomach, intestine, spleen and cardiac muscle which were more intense than in Cases when the mentionedcompounds were administered singly. When a lower dose of selenium (0.08 ppm) together with fenitrothion (40 mg/kg b.m.) was used there was a decrease of disorders in examined organs. Moreover, the changes were even less intense than when selenium (0.40 ppm) or fenitrothion (40 mg/kg h.m.) were administered as a single toxicant.Thus, it was concluded that selenium at a dose of 0.08 ppm protected the rats by limiting the toxic activity of Ienitrothion

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN